Obesity & metabolic treatment knowledge base

Understand obesity treatment before choosing what comes next.

Independent, evidence-based guides to medical weight management, GLP-1 therapy, bariatric surgery, metabolic disease and long-term follow-up — written so a decision can be made with a specialist, not before one.

Operated by DYPHI Inc., a registered international patient facilitator in the Republic of Korea. NextWeight provides general education; diagnosis, prescribing, and treatment decisions are made by licensed medical institutions.

Conditions

Obesity treatment may affect more than body weight.

Weight change can influence several obesity-related conditions. Effects vary by individual and by treatment, and any change should be monitored by the clinicians managing each condition.

Type 2 diabetes

Weight loss and metabolic surgery may improve glycaemic control, and can lead to remission in some selected patients. Read the evidence →

GERD after sleeve

Why reflux can appear or worsen after sleeve gastrectomy, and what the options are. Read more →

Weight regain

Why weight can return after medication or surgery, and when revision is considered. Read more →

Obstructive sleep apnea

Weight reduction may reduce the severity of sleep apnea for some people, but treatment such as CPAP is decided by a sleep specialist.

Fatty liver disease

Weight loss is associated with improvement in metabolic-associated fatty liver disease in many patients, though evidence and response vary.

Joint & mobility limitations

Reducing weight may ease load-related joint pain and improve mobility for some patients, alongside appropriate physiotherapy or orthopaedic care.

Explore all conditions →

Evidence at a glance

What the published evidence shows.

Three figures patients most often weigh when comparing surgery with medication. Each reflects a specific study population and time point, and does not predict what will happen for any individual.

28.3%

Mean total weight loss with bariatric surgery

Adults with class II–III obesity in a clinical weight-loss subset, measured over two years.

Source: JAMA Surgery, 2025 cohort study.

10.3%

Mean total weight loss with GLP-1 receptor agonists

Same cohort and time frame, in patients treated with GLP-1 receptor agonists rather than surgery.

Source: JAMA Surgery, 2025 cohort study.

~⅔

Of weight loss regained after stopping semaglutide

Approximately two-thirds of prior weight loss regained within one year of treatment withdrawal.

Source: STEP 1 trial extension.

These are population-level results reported in cited studies. They summarise averages across groups and do not establish what any individual will experience; effectiveness, risks, and durability depend on personal medical circumstances assessed by a specialist. See what the evidence shows

Bariatric surgery in Korea

A nationally organised bariatric surgery system with published registry data.

Korea combines KSMBS surgeon accreditation, electronic registry reporting, multidisciplinary hospital care, and clinical experience with obesity-related metabolic disease in Asian populations.

7,377

Patients included in the 2019–2022 KSMBS report

58

Participating institutions

0

Recorded deaths during the four-year registry period

Registry findings do not guarantee individual outcomes. Hospital, surgeon, procedure, and patient risk must be evaluated separately.

Considering medical treatment in Korea?

NextWeight provides general, evidence-based educational information. For individual hospital coordination and international-patient support in Korea, continue to Kordy.

Continue with Kordy